From what we can see, insiders were net buyers in TScan Therapeutics, Inc.'s (NASDAQ:TCRX ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While ...

Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

Looking at TScan Therapeutics, Inc.'s (NASDAQ:TCRX ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders ...

Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to ...

Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary ...

Amgen Inc AMGN and TScan Therapeutics Inc TCRX announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in ...

In the preceding three months, 6 analysts have released ratings for TScan Therapeutics (NASDAQ:TCRX), presenting a wide array of perspectives from bullish to bearish. The following table summarizes ...

All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with ...

To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities ...

Amgen and TScan Therapeutics announced a collaboration Tuesday morning to pursue novel targets in Crohn’s disease. As part of the deal, Amgen will pay TScan $30 million up front, with the potential ...

RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning WALTHAM, Mass, May 29, 2024 ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company specializing in T-cell receptor (TCR) engineered T cell therapies, stands at a critical juncture in its development pipeline. With key ...